Recor Medical's New Approval from CMS for Hypertension Treatment
Recor Medical, a forward-thinking medical technology company, has made significant strides in improving hypertension management. They recently celebrated a major milestone with the announcement that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted their innovative Paradise Ultrasound Renal Denervation (uRDN) system Transitional Pass-Through (TPT) payment status. This approval is pivotal as it signifies an enhanced reimbursement framework for a procedure that directly addresses uncontrolled hypertension, providing newfound hope for many patients.
Understanding the Paradise uRDN System
The Paradise uRDN system is a unique, first-of-its-kind technology that utilizes ultrasound to deliver treatment aimed at managing high blood pressure. This innovative approach works by precisely targeting and denervating the sympathetic nerves surrounding the renal arteries, which are often overactive in patients suffering from hypertension. Unlike traditional methods, the Paradise system applies two to three doses of concentrated ultrasound energy, which is carefully controlled to ensure maximum efficacy and safety during treatment.
How the Procedure Works
The procedure features the exclusive HydroCooling™ system. This integral component circulates sterile water through the balloon catheter during treatment, thus protecting the arterial walls while the ultrasound energy works to achieve the desired therapeutic effect. The ease of the procedure, which takes only a few moments, coupled with the precision of the technology, positions the Paradise uRDN system as a valuable alternative for patients who have struggled to control their blood pressure through conventional methods like lifestyle changes or medications.
Impact of TPT Payment Approval
The recent CMS TPT approval introduces a significant change in how medical facilities can assist patients with hypertension. Lara Barghout, president and CEO of Recor Medical, commented on the TPT's implications, emphasizing that this development broadens access to a groundbreaking treatment option. It not only underscores the safety and efficacy of the Paradise uRDN system but also creates a financial incentive for healthcare providers to adopt this innovative therapy.
Recognizing a New Device Category
Alongside the TPT approval, CMS has established a new distinct device category specifically for ultrasound renal denervation, identified by the code C1736: Catheter Renal Denervation, Ultrasound. This recognition further highlights the exceptional nature of the Paradise technology, noting that it significantly differs from existing treatments available in the healthcare landscape.
Addressing the Hypertension Crisis
Hypertension poses a serious global health challenge, contributing heavily to cardiovascular complications and mortality rates. Recor Medical aims to mitigate these issues with its proven technology. The company’s commitment to improving patient outcomes is evident, especially considering the recent FDA approval for the Paradise system for hypertension treatment. This device offers patients a supplementary option when traditional treatments have failed, thereby addressing the urgent needs of those with mild-to-moderate and resistant hypertension.
Ongoing Research and Development
As part of their dedication to advancing healthcare, Recor Medical is actively continuing its research and clinical studies focusing on the Paradise uRDN system. They are conducting the Global Paradise System Registry in Europe and the UK, alongside initiating a post-approval study in the US. These endeavors are crucial in gathering further data on the long-term effectiveness and safety of the device, ensuring that safety and efficacy remain at the forefront of hypertension management.
About Recor Medical
Recor Medical, based in Palo Alto, California, is at the cutting edge of hypertension treatment technology as a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd. Their mission is clear: to transform the management of hypertension through pioneering technologies such as the Paradise uRDN system, which has already displayed promising outcomes across multiple clinical studies.
Looking to the Future
With the support from CMS and ongoing developments in technology and research, Recor Medical is well-positioned to lead the charge against hypertension. This innovation stands to change the lives of many individuals facing challenges with their blood pressure control, further solidifying Recor's commitment to addressing pressing health concerns in the community.
Frequently Asked Questions
What is the Paradise Ultrasound Renal Denervation system?
The Paradise uRDN system is an innovative ultrasound-based treatment designed to manage uncontrolled hypertension by targeting overactive nerves around the renal arteries.
What does the CMS TPT payment approval signify?
The TPT payment approval means enhanced reimbursement for procedures using the Paradise system, increasing access for patients who need this treatment.
What are the benefits of using the Paradise system?
The benefits include a non-invasive procedure with a focused ultrasound application that provides a viable option for patients unresponsive to traditional hypertension treatments.
How does the HydroCooling™ system work?
The HydroCooling™ system circulates sterile water through the catheter balloon during the procedure to protect the renal artery while delivering the ultrasound treatment.
What future studies is Recor Medical conducting?
Recor Medical is conducting ongoing research, including the Global Paradise System Registry and a post-approval study in the US, to evaluate the extended effectiveness of the Paradise uRDN system.
